Genelux is a late clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for aggressive and difficult-to-treat cancers. Its lead product, Olvi-Vec (olvimulogene nanivacirepvec), is a modified vaccinia virus designed to selectively kill tumor cells and induce personalized immune responses. Olvi-Vec is in a Phase 3 trial for platinum-resistant/refractory ovarian cancer, a Phase 2 trial for recurrent NSCLC, and a Phase 1b/2 trial in China for recurrent SCLC.
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-19 | 2025-12-31 | 0001493152-26-011616 | EDGAR | 99K words |
| 2025-03-28 | 2024-12-31 | 0001641172-25-001184 | EDGAR | 105K words |
| 2024-03-29 | 2023-12-31 | 0001493152-24-011946 | EDGAR | 117K words |
| 2023-03-29 | 2022-12-31 | 0001193125-23-083829 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-13 | 2026-06-30 | 0001493152-26-037667 | EDGAR | 23K words |
| 2025-11-05 | 2025-09-30 | 0001493152-25-020874 | EDGAR | 29K words |
| 2025-08-07 | 2025-06-30 | 0001641172-25-022583 | EDGAR | 28K words |
| 2025-05-06 | 2025-03-31 | 0001641172-25-008838 | EDGAR | 72K words |
| 2024-11-14 | 2024-09-30 | 0001493152-24-045790 | EDGAR | 78K words |
| 2024-08-14 | 2024-06-30 | 0001493152-24-032145 | EDGAR | 78K words |
| 2024-05-09 | 2024-03-31 | 0001493152-24-018436 | EDGAR | 74K words |
| 2023-11-14 | 2023-09-30 | 0001493152-23-041151 | EDGAR | 80K words |
| 2023-08-14 | 2023-06-30 | 0001493152-23-027998 | EDGAR | 78K words |
| 2023-05-15 | 2023-03-31 | 0001493152-23-016832 | EDGAR | 74K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-19 | 0001493152-26-011649 | EDGAR | 23K words |
| 2026-02-02 | 0001493152-26-004755 | EDGAR | 0K words |
| 2026-01-08 | 0001493152-26-000989 | EDGAR | 1K words |
| 2026-01-05 | 0001493152-26-000270 | EDGAR | 2K words |
| 2026-01-02 | 0001493152-26-000115 | EDGAR | 6K words |
| 2025-09-03 | 0001641172-25-026390 | EDGAR | 1K words |
| 2025-03-25 | 0001641172-25-000642 | EDGAR | 1K words |
| 2025-03-25 | 0001641172-25-000528 | EDGAR | 0K words |
| 2025-02-03 | 0001493152-25-004554 | EDGAR | 4K words |
| 2024-11-08 | 0001493152-24-044258 | EDGAR | 0K words |
64 total filings indexed. 40 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001231457 |
| Ticker | GNLX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Headquarters | San Diego, California |
| Website | https://www.genelux.com |
| Listed | 2023-01-26 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/GNLX (~200 tokens, structured JSON with cryptographic provenance)